CA2723648A1 - Methods for identification and use of agents targeting cancer stem cells - Google Patents
Methods for identification and use of agents targeting cancer stem cells Download PDFInfo
- Publication number
- CA2723648A1 CA2723648A1 CA2723648A CA2723648A CA2723648A1 CA 2723648 A1 CA2723648 A1 CA 2723648A1 CA 2723648 A CA2723648 A CA 2723648A CA 2723648 A CA2723648 A CA 2723648A CA 2723648 A1 CA2723648 A1 CA 2723648A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cancer
- compound
- cell
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract 109
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 94
- 201000011510 cancer Diseases 0.000 title claims abstract 84
- 210000000130 stem cell Anatomy 0.000 title claims abstract 38
- 230000008685 targeting Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 51
- 230000012010 growth Effects 0.000 claims abstract 21
- 230000004083 survival effect Effects 0.000 claims abstract 18
- 239000000090 biomarker Substances 0.000 claims abstract 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract 9
- 238000011282 treatment Methods 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims 131
- 238000012360 testing method Methods 0.000 claims 66
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 18
- 102000000905 Cadherin Human genes 0.000 claims 17
- 108050007957 Cadherin Proteins 0.000 claims 17
- 230000005764 inhibitory process Effects 0.000 claims 15
- 238000003556 assay Methods 0.000 claims 11
- 230000035755 proliferation Effects 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 10
- 150000002611 lead compounds Chemical class 0.000 claims 9
- ONCZDRURRATYFI-QTCHDTBASA-N methyl (2z)-2-methoxyimino-2-[2-[[(e)-1-[3-(trifluoromethyl)phenyl]ethylideneamino]oxymethyl]phenyl]acetate Chemical compound CO\N=C(/C(=O)OC)C1=CC=CC=C1CO\N=C(/C)C1=CC=CC(C(F)(F)F)=C1 ONCZDRURRATYFI-QTCHDTBASA-N 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 230000001939 inductive effect Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 102100032912 CD44 antigen Human genes 0.000 claims 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 5
- 108091023040 Transcription factor Proteins 0.000 claims 5
- 102000040945 Transcription factor Human genes 0.000 claims 5
- 230000000977 initiatory effect Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 4
- -1 Klf8 Proteins 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 238000004114 suspension culture Methods 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims 3
- 239000005660 Abamectin Substances 0.000 claims 3
- 229920001817 Agar Polymers 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 claims 3
- 239000004189 Salinomycin Substances 0.000 claims 3
- 102000006280 Twist-Related Protein 1 Human genes 0.000 claims 3
- 108010083162 Twist-Related Protein 1 Proteins 0.000 claims 3
- 229950008167 abamectin Drugs 0.000 claims 3
- 239000008272 agar Substances 0.000 claims 3
- 239000002458 cell surface marker Substances 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 231100000673 dose–response relationship Toxicity 0.000 claims 3
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 claims 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 3
- 229960005420 etoposide Drugs 0.000 claims 3
- 201000005296 lung carcinoma Diseases 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 claims 3
- 231100001221 nontumorigenic Toxicity 0.000 claims 3
- 229960001548 salinomycin Drugs 0.000 claims 3
- 235000019378 salinomycin Nutrition 0.000 claims 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- 101100239628 Danio rerio myca gene Proteins 0.000 claims 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims 2
- 102100040834 FXYD domain-containing ion transport regulator 5 Human genes 0.000 claims 2
- 108700031316 Goosecoid Proteins 0.000 claims 2
- 102000050057 Goosecoid Human genes 0.000 claims 2
- 108700039143 HMGA2 Proteins 0.000 claims 2
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 claims 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims 2
- 101150073387 Hmga2 gene Proteins 0.000 claims 2
- 102100025061 Homeobox protein Hox-B7 Human genes 0.000 claims 2
- 101000893718 Homo sapiens FXYD domain-containing ion transport regulator 5 Proteins 0.000 claims 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims 2
- 101001077539 Homo sapiens Homeobox protein Hox-B7 Proteins 0.000 claims 2
- 101000972291 Homo sapiens Lymphoid enhancer-binding factor 1 Proteins 0.000 claims 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 claims 2
- 101150039798 MYC gene Proteins 0.000 claims 2
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 2
- 101710143583 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 Proteins 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 101710175789 Tafazzin Proteins 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 claims 2
- 101000818331 Xenopus tropicalis Forkhead box protein C2 Proteins 0.000 claims 2
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 claims 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 2
- 201000007180 bile duct carcinoma Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000001531 bladder carcinoma Diseases 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 238000003501 co-culture Methods 0.000 claims 2
- 230000005757 colony formation Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 2
- 229960000640 dactinomycin Drugs 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 238000007876 drug discovery Methods 0.000 claims 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000002825 functional assay Methods 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- 208000025189 neoplasm of testis Diseases 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 2
- 201000010198 papillary carcinoma Diseases 0.000 claims 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 2
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000588 tumorigenic Toxicity 0.000 claims 2
- 230000000381 tumorigenic effect Effects 0.000 claims 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- 102000007372 Ataxin-1 Human genes 0.000 claims 1
- 108010032963 Ataxin-1 Proteins 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100024210 CD166 antigen Human genes 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 102100037241 Endoglin Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 102100023513 Flotillin-2 Human genes 0.000 claims 1
- 101710164820 Flotillin-2 Proteins 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 101710191666 Lactadherin Proteins 0.000 claims 1
- 102100039648 Lactadherin Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 101150044441 PECAM1 gene Proteins 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 108010067902 Peptide Library Proteins 0.000 claims 1
- 102100040120 Prominin-1 Human genes 0.000 claims 1
- 238000004617 QSAR study Methods 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 claims 1
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000010293 colony formation assay Methods 0.000 claims 1
- 238000005138 cryopreservation Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 230000017066 negative regulation of growth Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100001274 therapeutic index Toxicity 0.000 claims 1
- 231100000027 toxicology Toxicity 0.000 claims 1
- 231100000747 viability assay Toxicity 0.000 claims 1
- 238000003026 viability measurement method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4394808P | 2008-04-10 | 2008-04-10 | |
| US61/043,948 | 2008-04-10 | ||
| US5356308P | 2008-05-15 | 2008-05-15 | |
| US61/053,563 | 2008-05-15 | ||
| PCT/US2009/002254 WO2009126310A2 (en) | 2008-04-10 | 2009-04-10 | Methods for identification and use of agents targeting cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2723648A1 true CA2723648A1 (en) | 2009-10-15 |
Family
ID=41162467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2723648A Abandoned CA2723648A1 (en) | 2008-04-10 | 2009-04-10 | Methods for identification and use of agents targeting cancer stem cells |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110191868A1 (enExample) |
| EP (2) | EP2274617A4 (enExample) |
| JP (2) | JP2011522515A (enExample) |
| CN (1) | CN102144163A (enExample) |
| CA (1) | CA2723648A1 (enExample) |
| WO (1) | WO2009126310A2 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| EP3061808B1 (en) | 2009-02-03 | 2020-08-12 | Koninklijke Nederlandse Akademie van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising said stem cells |
| US20120295346A1 (en) * | 2009-07-22 | 2012-11-22 | Tufts University | Methods and compositions for modulating membrane potential to influence cell behavior |
| EP2322927A1 (en) * | 2009-11-16 | 2011-05-18 | Deutsches Krebsforschungszentrum | Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer |
| WO2011096728A2 (en) | 2010-02-03 | 2011-08-11 | Samsung Life Public Welfare Foundation | Method for proliferating stem cells by activating c-met/hgf signaling and notch signaling |
| AU2011243958B2 (en) | 2010-04-18 | 2015-01-22 | Yeda Research And Development Co. Ltd. | Molecules and methods of using same for treating ErbB/ErbB ligands associated diseases |
| US10095842B2 (en) * | 2010-05-28 | 2018-10-09 | Salgomed, Inc. | Methods for artificial combinatorial control of biological systems |
| US20110293525A1 (en) * | 2010-05-29 | 2011-12-01 | Board Of Trustees Of The University Of Illinois | Tumor stem cells |
| CA2806726A1 (en) * | 2010-08-02 | 2012-02-09 | The Broad Institute, Inc. | Prediction of and monitoring cancer therapy response based on gene expression profiling |
| CA2809979A1 (en) | 2010-09-01 | 2012-03-08 | Whitehead Institute For Biomedical Research | Compositions and methods for modulating emt and uses thereof |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2012031280A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| GB201100180D0 (en) * | 2011-01-06 | 2011-02-23 | Capsant Neurotechnologies Ltd | Tumour cell and tissue culture |
| FR2970179B1 (fr) * | 2011-01-11 | 2013-01-18 | Centre Nat Rech Scient | Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques |
| EP2680853A4 (en) | 2011-02-28 | 2014-08-06 | Univ Mcmaster | TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS |
| WO2013105985A1 (en) | 2011-02-28 | 2013-07-18 | Philadelphia Health & Education Corporation | Small molecule inhibitors of rad51 recombinase and methods thereof |
| CA2830613A1 (en) * | 2011-03-24 | 2012-09-27 | The Rogosin Institute | Assay for screening compounds that selectively decrease the number of cancer stem cells |
| AU2012235767B2 (en) * | 2011-03-27 | 2016-02-04 | Oncostem Diagnostics (Mauritius) Pvt. Ltd. | Markers for identifying tumor cells, methods and kit thereof |
| US9351988B2 (en) | 2011-05-02 | 2016-05-31 | Universite De Geneve | Macrocyclic lactones and use thereof |
| US9791449B2 (en) * | 2011-06-03 | 2017-10-17 | The General Hospital Corporation | Ovarian cancer stem cells and methods of isolation and uses thereof |
| US20140294725A1 (en) | 2011-07-08 | 2014-10-02 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| WO2013032907A1 (en) * | 2011-08-26 | 2013-03-07 | The Broad Institute, Inc. | Compounds and methods for the treatment of cancer stem cells |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| US9670549B2 (en) | 2011-11-10 | 2017-06-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene expression signatures of neoplasm responsiveness to therapy |
| WO2013071066A1 (en) * | 2011-11-11 | 2013-05-16 | The Broad Institute, Inc. | Signatures associated with the response to cancer therapy |
| CN103127052A (zh) * | 2011-12-05 | 2013-06-05 | 维瑞斯特姆有限公司 | 治疗组合物和相关使用方法 |
| CN103193841A (zh) | 2012-01-06 | 2013-07-10 | 维瑞斯特姆有限公司 | 治疗性化合物及相关使用方法 |
| US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
| CN103243074B (zh) * | 2012-02-14 | 2014-10-01 | 中国科学院动物研究所 | 一种人结直肠癌肿瘤细胞系及其制备方法和应用 |
| US20150017134A1 (en) * | 2012-03-01 | 2015-01-15 | Whitehead Institute For Biomedical Research | Emt-inducing transcription factors cooperate with sox9 |
| DK2823040T3 (en) * | 2012-03-06 | 2018-11-19 | Cellect Biotherapeutics Ltd | DEVICES AND METHODS FOR SELECTING APOPTOSE SIGNALING RESISTANT CELLS AND APPLICATIONS THEREOF |
| US9080154B1 (en) * | 2012-04-02 | 2015-07-14 | Bowling Green State University | Cancer stem cell survivor lines |
| KR101463183B1 (ko) | 2012-06-05 | 2014-11-21 | 연세대학교 산학협력단 | 암 줄기세포 특성에 기초한 암의 신규한 치료용 타겟 및 바이오마커 |
| CN110079580B (zh) | 2012-06-22 | 2022-12-06 | 真蒂奥姆责任有限公司 | 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法 |
| WO2014009245A2 (en) * | 2012-07-09 | 2014-01-16 | Qithera Gmbh | Novel drug target indentification methods |
| HUE049569T2 (hu) | 2012-08-09 | 2020-09-28 | Celgene Corp | Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US10106778B2 (en) | 2012-11-08 | 2018-10-23 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| GB2513299A (en) * | 2013-03-12 | 2014-10-29 | Cellact Pharma Gmbh Biomedizinzentrum | Compounds for targeting cancer stem cells |
| US20160003808A1 (en) * | 2013-03-14 | 2016-01-07 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition |
| CN104840961B (zh) * | 2014-02-14 | 2016-03-23 | 马立伟 | 癌症干细胞敏感剂在制备抗癌症干细胞试剂盒中的应用 |
| US20170082610A1 (en) * | 2014-03-17 | 2017-03-23 | Agency For Science, Technology And Research | METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-kB TRANSLOCATION |
| AU2015233370A1 (en) | 2014-03-20 | 2016-09-22 | Centre National De La Recherche Scientifique (Cnrs) | Use of compounds inhibiting Apelin / APJ / GP130 signaling for treating cancer |
| EP2921855A1 (en) * | 2014-03-20 | 2015-09-23 | Centre National de la Recherche Scientifique (CNRS) | Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer |
| US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
| US20170191032A1 (en) * | 2014-05-06 | 2017-07-06 | The Board Of Regents Of The University Of Texas System | Identification and isolation of neural stem cells and neurosphere initiating cells |
| US10597633B2 (en) | 2014-05-16 | 2020-03-24 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture method for organoids |
| TWI794885B (zh) | 2014-05-19 | 2023-03-01 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
| JP6277894B2 (ja) * | 2014-07-08 | 2018-02-14 | 株式会社島津製作所 | 上皮間葉転換の有無を判別する方法 |
| JP7016466B2 (ja) * | 2014-09-24 | 2022-02-07 | 国立研究開発法人国立がん研究センター | 扁平上皮がんに対する化学放射線療法の有効性を評価するための方法 |
| US20170304251A1 (en) * | 2014-10-09 | 2017-10-26 | Paul Anthony Spagnuolo | Avocado-derived lipids for use in treating leukemia |
| EP3026122A1 (en) * | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| GB201421092D0 (en) * | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| GB201421094D0 (en) * | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| WO2016098041A1 (en) * | 2014-12-18 | 2016-06-23 | Saarum Sciences Private Ltd | Establishment and use of an in vitro platform for emt |
| CN104725511B (zh) * | 2015-02-16 | 2018-01-12 | 华南农业大学 | 一种猪肠道干细胞的分离培养方法 |
| KR20180021697A (ko) * | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| CN108513537A (zh) * | 2015-09-23 | 2018-09-07 | 米纳瓦生物技术公司 | 筛选分化干细胞的试剂的方法 |
| GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| CN106701886B (zh) * | 2016-12-16 | 2021-06-22 | 管晓翔 | 一种三阴性乳腺癌细胞上皮间质转换过程中对内皮细胞分泌功能影响的检测方法 |
| JP2021502329A (ja) * | 2017-11-08 | 2021-01-28 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｒｈｏａドミナントネガティブフォームを使用して癌を治療するための組成物および方法 |
| EP3502700A1 (en) * | 2017-12-21 | 2019-06-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods based on the detection of rad51 foci in tumor cells |
| CN108410986B (zh) * | 2018-02-26 | 2021-06-22 | 中国人民解放军总医院 | Cdh6促进骨肉瘤生长和转移 |
| US10146914B1 (en) | 2018-03-01 | 2018-12-04 | Recursion Pharmaceuticals, Inc. | Systems and methods for evaluating whether perturbations discriminate an on target effect |
| CN109512833B (zh) * | 2018-12-04 | 2020-10-30 | 天津医科大学总医院 | E2f6抑制剂的功能与用途 |
| CN110082536B (zh) * | 2019-04-17 | 2022-06-10 | 广州医科大学附属肿瘤医院 | 一种乳腺癌细胞标志物细胞因子群及其应用 |
| EP4121111A4 (en) * | 2020-03-20 | 2024-05-15 | University of Houston System | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS |
| US12116637B2 (en) | 2020-07-24 | 2024-10-15 | The Regents Of The University Of Michigan | Compositions and methods for detecting and treating high grade subtypes of uterine cancer |
| CN116783487A (zh) * | 2020-08-05 | 2023-09-19 | 乔斯林糖尿病中心公司 | 终末期肾病生物标记物组 |
| EP4214714A4 (en) * | 2020-09-21 | 2024-10-16 | Mestastop Solutions Private Limited | SYSTEMS AND METHODS FOR PREDICTING CANCER METASTASIS AND DRUG SCREENING |
| CN112730840B (zh) * | 2021-01-29 | 2023-10-17 | 章毅 | 鉴别cd44和cd24分子表型的方法 |
| CN113125689B (zh) * | 2021-03-29 | 2022-02-22 | 创芯国际生物科技(广州)有限公司 | 一种新型mtt细胞活力检测试剂盒及其应用 |
| CN114181102B (zh) * | 2021-11-10 | 2023-06-23 | 深圳市检验检疫科学研究院 | 己雷琐辛半抗原、人工抗原、抗体及其合成方法和应用 |
| CN115992240A (zh) * | 2022-10-28 | 2023-04-21 | 中山大学附属第三医院 | E2f转录因子2作为治疗靶点在制备预防和/或治疗多发性骨髓瘤的药物中的应用 |
| CN115948558B (zh) * | 2023-01-19 | 2025-04-11 | 重庆医科大学 | 乳腺癌肺特异性转移的标志物及其药物组合物与应用 |
| CN117347621B (zh) * | 2023-08-25 | 2024-03-12 | 广东省农业科学院农业生物基因研究中心 | 一种用蛋白模拟抗原-纳米抗体检测黄曲霉毒素b1的方法 |
| WO2025170878A1 (en) * | 2024-02-05 | 2025-08-14 | Exvivo Labs Inc | Methods for high-throughput drug screens at clonal resolution |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| EP0336248A1 (de) | 1988-03-31 | 1989-10-11 | Hoechst Aktiengesellschaft | Am F-Ring substituierte Nigericinderivate, Verfahren zu deren Herstellung, diese enthaltende Mittel und Verwendung derselben als antiviral wirksam und antibakteriell wirksame Substanzen |
| EP0346760A2 (de) | 1988-06-14 | 1989-12-20 | Hoechst Aktiengesellschaft | Nigericinderivate, Verfahren zu deren Herstellung, diese enthaltende Mittel und Verwendung derselben |
| DE3829450A1 (de) | 1988-08-31 | 1990-03-01 | Hoechst Ag | Nigericinderivate, verfahren zu deren herstellung, diese enthaltende mittel und verwendung derselben |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5229415A (en) | 1992-03-24 | 1993-07-20 | Merck & Co., Inc. | Alkylthio alkyl avermectins are active antiparasitic agents |
| GB9312154D0 (en) | 1993-06-12 | 1993-07-28 | Pfizer Ltd | Antiparasitic agents |
| US20020042079A1 (en) * | 1994-02-01 | 2002-04-11 | Sanford M. Simon | Methods and agents for measuring and controlling multidrug resistance |
| WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
| US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
| CA2294928C (en) | 1997-07-23 | 2003-01-14 | Pfizer Inc. | Production of avermectin compounds |
| US8334238B2 (en) | 1998-04-17 | 2012-12-18 | Rigel, Inc. | Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries |
| ATE360086T1 (de) | 2000-02-24 | 2007-05-15 | Kyowa Hakko Kogyo Kk | Verfahren zur herstellung von avermectinderivaten |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| SE0102168D0 (sv) * | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
| WO2003035661A1 (en) | 2001-10-26 | 2003-05-01 | Centre National De La Recherche Scientifique | Derivatives of etoposide and analogs, and pharmaceutical compositions containing them |
| TW200300416A (en) | 2001-11-27 | 2003-06-01 | Bristol Myers Squibb Co | Method of synthesizing a paclitaxel derivative |
| WO2003048166A1 (en) | 2001-12-03 | 2003-06-12 | Universitätsklinikum Charite Der Humboldt-Universität Zu Berlin Technologie Transferstelle | Podophyllotoxins as antiproliferative agents |
| US6566393B1 (en) | 2002-06-21 | 2003-05-20 | The University Of North Carolina At Chapel Hill | Etoposide analogs and methods of use thereof |
| US7176236B2 (en) | 2002-06-21 | 2007-02-13 | University Of North Carolina At Chapel Hill | Water-soluble etoposide analogs and methods of use thereof |
| US20050026866A1 (en) | 2002-08-02 | 2005-02-03 | Pawelek John M. | Agents and methods for treatment of disease by oligosaccharide targeting agents |
| CA2598707A1 (en) | 2004-02-24 | 2005-09-09 | Phytogen Life Sciences Inc. | Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel |
| CA2572223C (en) * | 2004-06-25 | 2014-08-12 | The Johns Hopkins University | Angiogenesis inhibitors |
| US20060040980A1 (en) * | 2004-08-20 | 2006-02-23 | Lind Stuart E | Ionophores as cancer chemotherapeutic agents |
| WO2006101925A2 (en) * | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| WO2006138275A2 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20090214483A1 (en) | 2005-06-30 | 2009-08-27 | Weinberg Robert A | Progenitor Cells and Uses Thereof |
| AU2006283040B2 (en) * | 2005-08-22 | 2011-08-25 | The Johns Hopkins University | Hedgehog pathway antagonists to treat disease |
| AU2006292278B2 (en) * | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| DE102007007750A1 (de) | 2006-08-17 | 2008-02-21 | Bayer Cropscience Ag | Avermectinderivate |
| FR2906465B1 (fr) | 2006-09-28 | 2008-11-28 | Galderma Sa | Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques chez l'homme |
| WO2008095165A2 (en) * | 2007-02-01 | 2008-08-07 | Dana-Farber Cancer Institute, Inc. | Cell co-culture systems and uses thereof |
| WO2009025854A1 (en) * | 2007-08-22 | 2009-02-26 | Burnham Institute For Medical Research | Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases |
| WO2010037134A2 (en) * | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
-
2009
- 2009-04-10 CA CA2723648A patent/CA2723648A1/en not_active Abandoned
- 2009-04-10 CN CN2009801219225A patent/CN102144163A/zh active Pending
- 2009-04-10 WO PCT/US2009/002254 patent/WO2009126310A2/en not_active Ceased
- 2009-04-10 EP EP20090729661 patent/EP2274617A4/en not_active Withdrawn
- 2009-04-10 US US12/937,070 patent/US20110191868A1/en not_active Abandoned
- 2009-04-10 EP EP11158438A patent/EP2385370A1/en not_active Withdrawn
- 2009-04-10 JP JP2011504009A patent/JP2011522515A/ja active Pending
-
2013
- 2013-10-28 US US14/065,311 patent/US20140294729A1/en not_active Abandoned
-
2014
- 2014-04-08 JP JP2014079322A patent/JP2014128294A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011522515A (ja) | 2011-08-04 |
| EP2274617A4 (en) | 2011-11-09 |
| EP2274617A2 (en) | 2011-01-19 |
| EP2385370A1 (en) | 2011-11-09 |
| US20140294729A1 (en) | 2014-10-02 |
| JP2014128294A (ja) | 2014-07-10 |
| WO2009126310A3 (en) | 2010-02-25 |
| US20110191868A1 (en) | 2011-08-04 |
| CN102144163A (zh) | 2011-08-03 |
| WO2009126310A2 (en) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2723648A1 (en) | Methods for identification and use of agents targeting cancer stem cells | |
| Yoshikawa et al. | xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma | |
| Wang et al. | CCL18 from tumor‐cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway | |
| Cui et al. | Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2 | |
| Gradilone et al. | Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization | |
| Cornelius et al. | Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma | |
| Cui et al. | FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways | |
| Angeloni et al. | Implications of stemness-related signaling pathways in breast cancer response to therapy | |
| Li et al. | O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer | |
| Xu et al. | N6-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRP1 | |
| Chen et al. | H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma | |
| JP2013520958A (ja) | 上皮間葉転換のバイオマーカーとしてａｘｌを使用する方法 | |
| Kwon et al. | Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer | |
| O'Toole et al. | Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors | |
| Ge et al. | RNA demethylase ALKBH5 suppresses tumorigenesis via inhibiting proliferation and invasion and promoting CD8+ T cell infiltration in colorectal cancer | |
| Chen et al. | IL‐1RA suppresses esophageal cancer cell growth by blocking IL‐1α | |
| Huang et al. | Overexpressed ACBD3 has prognostic value in human breast cancer and promotes the self-renewal potential of breast cancer cells by activating the Wnt/beta-catenin signaling pathway | |
| Gunes et al. | Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma | |
| Xu et al. | Hsa_circ_0018818 knockdown suppresses tumorigenesis in non-small cell lung cancer by sponging miR-767-3p | |
| Chen et al. | Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling | |
| Yang et al. | Phosphorylase kinase β represents a novel prognostic biomarker and inhibits malignant phenotypes of liver cancer cell | |
| Lin et al. | Pin1 positively affects tumorigenesis of esophageal squamous cell carcinoma and correlates with poor survival of patients | |
| Chebouti et al. | Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis? | |
| Tan et al. | Bizarre giant cells in human angiosarcoma exhibit chemoresistance and contribute to poor survival outcomes | |
| Penzo et al. | JHDM1B expression regulates ribosome biogenesis and cancer cell growth in a p53 dependent manner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140409 |
|
| FZDE | Discontinued |
Effective date: 20171130 |